12 Month Price Forecast For BOLD
Distance to BOLD Price Forecasts
BOLD Price Momentum
🤔 Considering Audentes (BOLD)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 2:34 AM UTC
BOLD Analyst Ratings & Price Targets
Based on our analysis of 13 Wall Street analysts, BOLD has a consensus that is bullish. The median price target is $14.50, with forecasts ranging from $14.00 to $15.00. Currently, there are 2 Buy ratings, 1 Hold ratings, and 0 Sell ratings.
With BOLD currently trading at $2.57, the median price forecast suggests a 464.2% upside. The most optimistic forecast comes from at , projecting a 483.7% upside, while at provides the most conservative target, suggesting a 444.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BOLD Analyst Consensus
BOLD Price Target Range
Latest BOLD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BOLD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 13, 2024 | Guggenheim | Yige Guo | Neutral | Downgrade | $0.00 |
| Apr 22, 2024 | Leerink Partners | Michael Cherny | Outperform | Initiates | $25.00 |
| Apr 22, 2024 | Piper Sandler | Joseph Catanzaro | Overweight | Initiates | $20.00 |
| Apr 22, 2024 | Guggenheim | Yige Guo | Buy | Initiates | $24.00 |
| Dec 9, 2019 | Evercore ISI Group | In-Line | Downgrade | $0.00 | |
| Dec 6, 2019 | JP Morgan | Neutral | Downgrade | $0.00 | |
| Dec 4, 2019 | SVB Leerink | Market Perform | Downgrade | $0.00 | |
| Dec 4, 2019 | Chardan Capital | Neutral | Downgrade | $60.00 | |
| Dec 3, 2019 | Citigroup | Neutral | Upgrade | $60.00 | |
| Dec 3, 2019 | BMO Capital | Market Perform | Downgrade | $60.00 | |
| Dec 3, 2019 | HC Wainwright & Co. | Neutral | Downgrade | $60.00 | |
| Dec 3, 2019 | Wedbush | Neutral | Downgrade | $0.00 | |
| Dec 3, 2019 | Piper Sandler | Neutral | Downgrade | $60.00 | |
| Dec 3, 2019 | Piper Jaffray | Neutral | Downgrade | $0.00 | |
| Dec 3, 2019 | Baird | Neutral | Upgrade | $0.00 | |
| Dec 3, 2019 | Raymond James | Market Perform | Downgrade | $0.00 | |
| Dec 3, 2019 | Guggenheim | Neutral | Downgrade | $0.00 | |
| Nov 19, 2019 | Evercore ISI Group | Outperform | Upgrade | $40.00 | |
| Oct 3, 2019 | Baird | Underperform | Initiates | $10.00 | |
| Sep 3, 2019 | Chardan Capital | Buy | Maintains | $50.00 |
Stocks Similar to Audentes Therapeutics Inc
The following stocks are similar to Audentes based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Audentes Therapeutics Inc (BOLD) Financial Data
Audentes Therapeutics Inc has a market capitalization of $57.31M with a P/E ratio of -0.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -41.2%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Audentes Therapeutics Inc (BOLD) Company Overview
About Audentes Therapeutics Inc
Develops cancer therapeutics for oncogene amplified tumors.
The company operates as a clinical-stage oncology firm, focusing on innovative cancer treatments that target extrachromosomal DNA to meet the needs of patients with specific tumor types. It generates revenue through the development of therapeutic candidates, such as BBI-355 and BBI-825, which are currently undergoing clinical trials to assess their efficacy and safety in treating various cancers.
Boundless Bio, Inc. was founded in 2018 and is based in San Diego, California. Its research emphasizes addressing unmet medical needs in oncology, particularly for patients with oncogene amplified tumors and resistance gene amplifications.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
72
CEO
Mr. Zachary Hornby
Country
United States
IPO Year
N/A
Website
boundlessbio.comAudentes Therapeutics Inc (BOLD) Latest News & Analysis
The Russell 2000 Index rose 0.4% in the first week of 2025, suggesting the "January Effect" may be gaining momentum after a poor performance in the previous month.
A rebound in the Russell 2000 suggests growing investor optimism and potential market recovery, signaling opportunities in small-cap stocks following a downturn.
The company will not progress BBI-825 in the STARMAP trial but is advancing a third ecDTx program, with development candidate nomination expected by mid-2025. Operating runway extended into 2027.
BBI-825's trial halt raises concerns about its viability, while leadership changes may impact strategy. Extended runway to 2027 offers some stability, but upcoming milestones are crucial for confidence.
Boundless Bio (Nasdaq: BOLD) will have CEO Zachary Hornby speak at Piper Sandler's 36th Annual Healthcare Conference, focusing on therapies for oncogene amplified cancers.
Boundless Bio's CEO speaking at a major healthcare conference signals potential investor interest and visibility, which could impact stock performance and market perception of the company's future.
Boundless Bio, Inc. (BOLD) Loses -19.52% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
1 month agoBoundless Bio, Inc. (BOLD) is in oversold territory, suggesting potential for a trend reversal, supported by analysts' consensus on raising earnings estimates.
Oversold conditions suggest a potential rebound for Boundless Bio, Inc. (BOLD), while raised earnings estimates indicate growing confidence, signaling possible upside for investors.
Enrollment is ongoing for BBI-355 POTENTIATE and BBI-825 STARMAP clinical trials, with initial proof-of-concept data anticipated in H2 2025.
Successful enrollment and upcoming proof-of-concept data in clinical trials can indicate potential drug efficacy, impacting stock valuations and investor sentiment in the biotech sector.
Boundless Bio (Nasdaq: BOLD) will be represented by CEO Zachary Hornby at the 2024 Guggenheim Global Healthcare Conference, focusing on therapies for oncogene amplified cancers.
Zachary Hornby's participation in a major healthcare conference highlights Boundless Bio's visibility and potential growth in oncology, which may attract investor interest and impact stock performance.
Frequently Asked Questions About BOLD Stock
What is Audentes Therapeutics Inc's (BOLD) stock forecast for 2025?
Based on our analysis of 13 Wall Street analysts, Audentes Therapeutics Inc (BOLD) has a median price target of $14.50. The highest price target is $15.00 and the lowest is $14.00.
Is BOLD stock a good investment in 2025?
According to current analyst ratings, BOLD has 2 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.57. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for BOLD stock?
Wall Street analysts predict BOLD stock could reach $14.50 in the next 12 months. This represents a 464.2% increase from the current price of $2.57. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Audentes Therapeutics Inc's business model?
The company operates as a clinical-stage oncology firm, focusing on innovative cancer treatments that target extrachromosomal DNA to meet the needs of patients with specific tumor types. It generates revenue through the development of therapeutic candidates, such as BBI-355 and BBI-825, which are currently undergoing clinical trials to assess their efficacy and safety in treating various cancers.
What is the highest forecasted price for BOLD Audentes Therapeutics Inc?
The highest price target for BOLD is $15.00 from at , which represents a 483.7% increase from the current price of $2.57.
What is the lowest forecasted price for BOLD Audentes Therapeutics Inc?
The lowest price target for BOLD is $14.00 from at , which represents a 444.7% increase from the current price of $2.57.
What is the overall BOLD consensus from analysts for Audentes Therapeutics Inc?
The overall analyst consensus for BOLD is bullish. Out of 13 Wall Street analysts, 2 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $14.50.
How accurate are BOLD stock price projections?
Stock price projections, including those for Audentes Therapeutics Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
